2022年糖尿病监测与治疗新技术学术会议:探索不止,展望糖尿病管理新未来!

2022-09-16 K.K MedSci原创

由中华医学会、中华医学会糖尿病学分会主办,上海交通大学附属第六人民医院协办的“中华医学会糖尿病学分会2022年糖尿病监测与治疗新技术学术会议”已于2022年9月16-17日在线

由中华医学会、中华医学会糖尿病学分会主办,上海交通大学附属第六人民医院协办的“中华医学会糖尿病学分会2022年糖尿病监测与治疗新技术学术会议”已于2022年9月16-17日在线上精彩呈现。本次会议邀请多位知名糖尿病和内分泌专家,围绕糖尿病监测与治疗新技术领域进行学术报告。会议继续延续原有的特色,介绍了血糖监测技术与治疗新技术的研究进展,会议内容注重先进性和实用性,普及和提高相结合。

9月16日下午14:00点,哈尔滨医科大学附属第四医院成志锋教授为大家分享了《未来糖尿病管理趋势》,分别从疫情下的糖尿病管理面临两大难题、新型CGM给两大难题带来解决方案、CGM新技术新进展三个方面进行了详细的讲述。

 

2021年IDF(第十版)统计:我国糖尿病由9000万增加至1.4个亿,增幅达56%,其中约7283.9万尚未被确诊,比例高达51.7%;糖尿病导致的死亡人数(20-79岁)高达140万,≤60岁糖尿病相关比例为3.9%;糖尿病相关医疗保健支出高达10526亿,人均糖尿病相关医疗保健支出为8488元。在各地新冠疫情时有爆出,疫情防控常态化的背景下,糖尿病管理面临院外管理和院内感染两大难题。

糖尿病新型工具——硅基动感CGM给两大难题带来解决方案

1.院外管理

硅基动感配备了覆盖糖尿病患者在居家场景下的信息化解决方案。患者在居家隔离期间也可以实现规律测糖,医生及患者亲友都可以远程管理。

2.院内感染

采用发射器与传感器一体式设计,使得发射器与传感器均为一次性使用,降低院内感染风险;免指血校准,从根本上减少了血液暴露风险;实施监测葡萄糖,无需医护扫描。可连续佩戴14天,并且配备了覆盖糖尿病患者在住院、门诊等场景下的信息化解决方案。

  

一项法国的观察性研究显示,1378例1型糖尿病患者在居家隔离期间使用CGM监测血糖,使用问卷来调查患者的行为变化,研究发现使用CGM监测血糖,在居家隔离2个月后,平均血糖有所改善。

此外,硅基动感CGM具有发射器与传感器一体式,免指血校准,实时监测等特点,配备了覆盖糖尿病患者在住院、门诊、居家等场景下的信息化解决方案。无需采血即可测糖,实现零血液接触风险,内分泌科医生可远程管理全院血糖,大大减少了临床操作工作量,减少院内感染风险。糖尿病患者居家也可以规律测糖,并将葡萄糖数据分享给医生和亲友,实现院外远程管理。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903876, encodeId=a1f219038e6b8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 14:23:59 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904720, encodeId=d08d1904e20a8, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 15 15:23:59 CST 2023, time=2023-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931723, encodeId=82021931e2357, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Nov 27 00:23:59 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089695, encodeId=2e802089695c8, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21b05213416, createdName=咸咸圈, createdTime=Thu Sep 22 08:22:11 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249419, encodeId=4bd0124941998, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 16 22:22:50 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903876, encodeId=a1f219038e6b8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 14:23:59 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904720, encodeId=d08d1904e20a8, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 15 15:23:59 CST 2023, time=2023-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931723, encodeId=82021931e2357, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Nov 27 00:23:59 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089695, encodeId=2e802089695c8, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21b05213416, createdName=咸咸圈, createdTime=Thu Sep 22 08:22:11 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249419, encodeId=4bd0124941998, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 16 22:22:50 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903876, encodeId=a1f219038e6b8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 14:23:59 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904720, encodeId=d08d1904e20a8, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 15 15:23:59 CST 2023, time=2023-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931723, encodeId=82021931e2357, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Nov 27 00:23:59 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089695, encodeId=2e802089695c8, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21b05213416, createdName=咸咸圈, createdTime=Thu Sep 22 08:22:11 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249419, encodeId=4bd0124941998, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 16 22:22:50 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903876, encodeId=a1f219038e6b8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 14:23:59 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904720, encodeId=d08d1904e20a8, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 15 15:23:59 CST 2023, time=2023-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931723, encodeId=82021931e2357, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Nov 27 00:23:59 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089695, encodeId=2e802089695c8, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21b05213416, createdName=咸咸圈, createdTime=Thu Sep 22 08:22:11 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249419, encodeId=4bd0124941998, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 16 22:22:50 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
    2022-09-22 咸咸圈

    有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1903876, encodeId=a1f219038e6b8, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Sun Dec 25 14:23:59 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904720, encodeId=d08d1904e20a8, content=<a href='/topic/show?id=85fa455346c' target=_blank style='color:#2F92EE;'>#学术会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45534, encryptionId=85fa455346c, topicName=学术会议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Tue Aug 15 15:23:59 CST 2023, time=2023-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931723, encodeId=82021931e2357, content=<a href='/topic/show?id=1a76e6753b9' target=_blank style='color:#2F92EE;'>#糖尿病管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76753, encryptionId=1a76e6753b9, topicName=糖尿病管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Nov 27 00:23:59 CST 2022, time=2022-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089695, encodeId=2e802089695c8, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21b05213416, createdName=咸咸圈, createdTime=Thu Sep 22 08:22:11 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249419, encodeId=4bd0124941998, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 16 22:22:50 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
    2022-09-16 医鸣惊人

    认真学习了

    0

相关资讯

JCEM:糖尿病患者体重变化后心血管疾病的风险

2型糖尿病患者18个月以上体重的增加和减少,特别是体重变化≥5%,可能是不良心血管结局的预警信号。

Cardiovasc Diabetol :连续血糖监测在心血管高危糖尿病患者中的作用

糖化血红蛋白A1c (HbA1c)是评估血糖控制的主要工具,对糖尿病并发症有很强的预测价值。

“练死肌肉”而已?NONONO!肌肉强化活动可降低10-17%全因死亡、心血管、总癌、糖尿病风险!

Br J Sports Med:肌肉强化活动与主要非传染性疾病的风险和死亡率较低有关:队列研究的系统评价和荟萃分析

糖尿病人较容易得的四类皮肤病

糖尿病皮肤病变是糖尿病的常见并发症。在临床上,以皮肤病变为首发症状或主诉前来就诊的糖尿病患者,约占皮肤科门诊患者总数的 2% ~3%,而住院糖尿病患者皮肤病变发生率也高达58.14%。

“噻唑烷二酮”联合二线口服降糖药治疗可降低晚期糖尿病合并COPD患者急性加重的风险

在COPD-T2DM患者中,无论采用双药或三药联合方案,TZDs联合治疗均与AECOPD风险降低相关,特别是在中重度复杂COPD人群中。